个人简介

周南博士，中山大学医学院副教授，博士生导师，中山大学逸仙学者计划“新锐学者”。2006-2010年就读于中山大学生命科学学院，获生物技术专业学士学位；2010-2015年就读于中山大学中山医学院，获微生物学专业博士学位；2016-2023年在美国宾夕法尼亚大学医学院开展博士后研究，主要研究B细胞淋巴瘤发生、发展与耐药的分子机制。周南博士以第一作者或共同一作将研究成果发表在Blood、Cancer Research和Leukemia等国际知名期刊，并受Blood杂志社邀请以第一作者撰写评论（Commentary）文章，于2023年11月加入中山大学医学院。

研究方向

弥漫大B细胞淋巴瘤（diffuse large B-cell lymphoma, DLBCL）是具有高度异质性与侵袭性、最常见的非霍奇金淋巴瘤，在R-CHOP标准一线治疗后仍然有约40%患者进展为复发或难治型，成为亟待解决的临床问题。本课题组综合运用CRISPR筛选、基因组学、转录组学、蛋白组学、生化分析与动物模型来研究B细胞淋巴瘤发生、发展与耐药的分子机制，进而研发新的靶向治疗药物。

招生招聘

本课题组长期招收博士研究生、硕士研究生、博士后和专职科研人员，我们将提供有竞争力的薪酬待遇与职业发展环境。

研究生招生学科专业

100100 基础医学-02免疫学，086000 生物与医药

联系方式

zhoun55@mail.sysu.edu.cn

著作

1. Zhou N, Busino L*. Targeting epigenetics and ferroptosis in DLBCL. Blood. 2023 Sep 28; 142(13): 1108-1109.

2. Zhou N, Choi J, Grothusen G, Kim BJ, Ren D, Cao Z, Liu Y, Li Q, Inamdar A, Beer T, Tang HY, Perkey E, Maillard I, Bonasio R, Shi J, Ruella M, Wan L, Busino L*. DLBCL-associated NOTCH2 mutations escape ubiquitin-dependent degradation and promote chemoresistance. Blood. 2023 Sep 14; 142(11): 973-988.

3. Saffie R#, Zhou N#, Rolland D, Onder O, Basrur V, Campbell S, Wellen KE, Elenitoba-Johnson KSJ, Capell BC, Busino L*. FBXW7 Triggers Degradation of KMT2D to Favor Growth of Diffuse Large B-cell Lymphoma Cells. Cancer Res. 2020 Jun 15; 80(12): 2498-2511.

4. Zhou N, Gutierrez-Uzquiza A, Zheng XY, Chang R, Vogl DT, Garfall AL, Bernabei L, Saraf A, Florens L, Washburn MP, Illendula A, Bushweller JH, Busino L*. RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation. Leukemia. 2019 Aug; 33(8): 2006-2021.
 
5. Choi J#, Zhou N#, Busino L*. KLHL6 is a tumor suppressor gene in diffuse large B-cell lymphoma. Cell Cycle. 2019 Feb; 18(3): 249-256.

6. Zhou N#, Pan T#, Zhang J, Li Q, Zhang X, Bai C, Huang F, Peng T, Zhang J, Liu C, Tao L, Zhang H*. Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV). J Biol Chem. 2016 Apr 22; 291(17): 9218-32.

7. Simoneschi D, Rona G, Zhou N, Jeong YT, Jiang S, Milletti G, Arbini AA, OSullivan A, Wang AA, Nithikasem S, Keegan S, Siu Y, Cianfanelli V, Maiani E, Nazio F, Cecconi F, Boccalatte F, Fenyo D, Jones DR, Busino L*, Pagano M*. CRL4AMBRA1 is a master regulator of D-type cyclins. Nature. 2021 Apr; 592(7856): 789-793

8. Wu K, Li Y, Zhang S, Zhou N, Liu B, Pan T, Zhang X, Luo H, Huang Z, Li X, Zhang H*, Zhang J*. Preferential Homing of Tumor-specific and Functional CD8+ Stem Cell-like Memory T Cells to the Bone Marrow. J Immunother. 2019 Jul/Aug; 42(6): 197-207.

9. Pan T, Peng Z, Tan L, Zou F, Zhou N, Liu B, Liang L, Chen C, Liu J, Wu L, Liu G, Peng Z, Liu W, Ma X, Zhang J, Zhu X, Liu T, Li M, Huang X, Zhang Y, Zhang H*. Nonsteroidal Anti-inflammatory Drugs Potently Inhibit the Replication of Zika Viruses by Inducing the Degradation of AXL. J Virol. 2018 Sep 26; 92(20): e01018-18.

10. Pan T, Zhang Y, Zhou N, He X, Chen C, Liang L, Duan X, Lin Y, Wu K, Zhang H*. A recombinant chimeric protein specifically induces mutant KRAS degradation and potently inhibits pancreatic tumor growth. Oncotarget. 2016 Jul 12; 7(28): 44299-44309.

11. Zhong F, Zhou N, Wu K, Guo Y, Tan W, Zhang H, Zhang X, Geng G, Pan T, Luo H, Zhang Y, Xu Z, Liu J, Liu B, Gao W, Liu C, Ren L, Li J, Zhou J, Zhang H*. A SnoRNA-derived piRNA interacts with human interleukin-4 pre-mRNA and induces its decay in nuclear exosomes. Nucleic Acids Res. 2015 Dec 2; 43(21): 10474-91.